Hip fractures and pain following proton therapy for management of prostate cancer

Raul Valery, Nancy P. Mendenhall, Romaine C. Nichols, Randal Henderson, Christopher G. Morris, Zhong Su, William M. Mendenhall, Christopher R. Williams, Zuofeng Li, Bradford S. Hoppe

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Background. Proton therapy (PT) for prostate cancer reduces rectal and bladder dose, but increases dose to the femoral necks. We assessed the risk of hip fracture and pain in men treated with PT for prostate cancer. Material and methods. From 2006 to 2008, 382 men were treated for prostate cancer and evaluated at six-month intervals after PT for toxicities at University of Florida Proton Therapy Institute (UFPTI). The WHO Fracture Risk Assessment Tool (FRAX) generated annual hip-fracture risk for the cohort. The WHO FRAX tool was utilized to generate the expected number of patients with hip fractures and the observed-to-expected ratio; confidence intervals and p-value were generated with the mid-P exact test. Univariate analysis of hip pain as a function of several prognostic factors was accomplished with Fisher's exact test. Results. Median follow-up was four years (range, 0.1-5.5 years). Per FRAX, 3.02 patients were expected to develop a hip fracture without PT. Three PT patients actually developed fractures for a rate of 0.21 fractures per 100 person-years of follow-up. There was an observed-expected ratio of 0.99 (p-value not significant). Forty-eight patients (13%) reported new pain in the hip during follow-up; three required prescription analgesics. Conclusion. PT for prostate cancer did not increase hip-fractures in the first four years after PT compared to expected rates in untreated men.

Original languageEnglish (US)
Pages (from-to)486-491
Number of pages6
JournalActa Oncologica
Issue number3
StatePublished - Apr 2013

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Hip fractures and pain following proton therapy for management of prostate cancer'. Together they form a unique fingerprint.

Cite this